快訊

Zhitong
2025.10.21 13:27

Chairman of the Novo Nordisk Foundation, Sorensen: The ability to produce proteins at scale with highly competitive costs will become a competitive advantage in the future of large-scale marketing of GLP-1 class drugs

來源：Zhitong 本文版權歸屬原作者/機構所有。
當前內容僅代表作者觀點，與本平台立場無關。內容僅供投資者參考，亦不構成任何投資建議。如對本平台提供的內容服務有任何疑問或建議，請聯絡我們。